@prefix this: . @prefix sub: . @prefix prov: . @prefix dct: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix v: . @prefix d: . @prefix dv: . @prefix dr: . @prefix dcat: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB00349 v:identifier "DB00349"; v:namespace "drugbank"; v:uri "http://bio2rdf.org/drugbank:DB00349"; v:x-identifiers.org ; dv:drugbank-id "APRD00307", "DB00349"; dv:x-ahfs ; dv:x-atc ; dv:x-cas ; dv:x-chebi ; dv:x-chemspider ; dv:x-dpd ; dv:x-kegg ; dv:x-ndc ; dv:x-pharmgkb ; dv:x-pubchemcompound ; dv:x-pubchemsubstance ; dv:x-wikipedia ; dct:description "Clobazam belongs to the 1,5-benzodiazepine class of drugs and is expected to have a better side-effect profile compared to older 1,4-benzodiazepines. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011. An oral suspension is expected to be available in 2013."@en; dct:identifier "drugbank:DB00349"; dct:title "Clobazam"@en; a dv:Drug; rdfs:label "Clobazam [drugbank:DB00349]"@en; rdfs:seeAlso , , . } sub:provenance { sub:assertion prov:wasDerivedFrom . dr:bio2rdf.dataset.drugbank.R3 dcat:distribution . dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime; prov:wasDerivedFrom . pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime; prov:wasDerivedFrom . prov:wasAttributedTo . } sub:publicationInfo { sub:signature.MCwCFD7bTl9x2dLP npx:hasPublicKey "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"; npx:hasSignature "MCwCFD7bTl9x2dLPoROU18zI3ooWTuTCAhQvBdYr4mk+UE7ZBjeqQcUTu/+6pQ=="; npx:signedBy instance: . this: dct:created "2018-03-30T11:11:04.042+02:00"^^xsd:dateTime; dct:license ; npx:hasSignatureElement sub:signature.MCwCFD7bTl9x2dLP; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dct:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }